Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.

Thrombosis research - 1 Jan 2013

Donovan Anna K, Smith Kenneth J, Ragni Margaret V

Abstract excerpt

BACKGROUND: Current anticoagulation guidelines suggest that optimal anticoagulation duration for unprovoked venous thromboembolism is determined by an individual risk assessment, balancing risks of anticoagulation bleeding with venous thromboembolism recurrence. Among individuals heterozygous for the factor V Leiden mutation, while venous thromboembolism recurrence risk is greater, the risk for bleeding is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Decision Support Techniques
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor V

Share to Markov Chains

Share to Quality of Life

Share to Risk Assessment

Share to Venous Thromboembolism

Source

Identifiers

PMID: 24112753
DOI: 10.1016/j.thromres.2013.09.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticoagulation duration in heterozygous factor V Leiden: a decision analysis.PMID 24112753Read ↗

Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis.Semantic proximity Read ↗

Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.Semantic proximity Read ↗

Testing for factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis.Semantic proximity Read ↗

Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.Semantic proximity Read ↗

Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.Semantic proximity Read ↗

Role of thrombophilia in deciding on the duration of anticoagulation.Semantic proximity Read ↗

Recommendations from the EGAPP Working Group: routine testing for Factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members.Semantic proximity Read ↗

Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.Semantic proximity Read ↗

Duration of anticoagulant treatment for venous thrombosis.Semantic proximity Read ↗

How to decide on the optimal duration of anticoagulatn therapy in carriers of the factor V Leiden mutation.Semantic proximity Read ↗

The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.Semantic proximity Read ↗

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.